10.64
-0.2(-1.85%)
Currency In USD
| Previous Close | 10.84 |
| Open | 10.74 |
| Day High | 10.93 |
| Day Low | 10.42 |
| 52-Week High | 17.15 |
| 52-Week Low | 9.8 |
| Volume | 99,923 |
| Average Volume | 180,330 |
| Market Cap | 279.27M |
| PE | -9.85 |
| EPS | -1.08 |
| Moving Average 50 Days | 12.31 |
| Moving Average 200 Days | 13.35 |
| Change | -0.2 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $11.75 as of February 21, 2026 at a share price of $10.64. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $146.58 as of February 21, 2026 at a share price of $10.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
GlobeNewswire Inc.
Jan 11, 2026 1:00 PM GMT
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and to
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
GlobeNewswire Inc.
Nov 06, 2025 5:19 AM GMT
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di
Benitec Biopharma Inc. Announces Proposed Public Offering
GlobeNewswire Inc.
Nov 05, 2025 9:43 PM GMT
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di